PharmaFocus Today – Page 32 – media

The birth of the youngest pharmaceutical company worth hundreds of billions of yuan

The World Lung Cancer Conference (WCLC), a leading global conference in the field of lung cancer treatment, has always been a central arena for innovative pharmaceutical companies to compete. At this year’s WCLC, several innovative Chinese pharmaceutical companies made their mark, with Baili Tianheng undoubtedly the most prominent. Its core product, the world’s first EGFR×HER3 bispecific ADC drug BL-B01D1 (Iza-bren) combined with osimertinib in the treatment of EGFR-mutated non-small cell lung cancer, has achieved an objective response rate (ORR) of 100%, with far-leading efficacy data. It has also achieved a historic breakthrough of a median progression-free survival (mPFS) of over 12 months in monotherapy. As of the close of September 12, the share price of Baili Tianheng’s A shares closed at 349.79 yuan per share, and the company’s total market value exceeded 140 billion yuan, making it the third innovative pharmaceutical company in the A-share market to join the “100 ...
- Source: drugdu
- 166
- September 16, 2025
Kexing Pharma partners with Thousand Oaks Biopharmaceuticals to enter the European and American biosimilar markets

Recently, Kexing Pharma have reached a strategic cooperation with Shanghai Thousand Oaks Biopharmaceutical Co., Ltd. (hereinafter referred to as “Thousand Oaks Bio”) to jointly develop the KXBS001 biosimilar, officially entering the European and American biosimilars market. The European Medicines Agency (EMA) recently released a draft plan to streamline the review process for biosimilar drug development, potentially opening a “fast track” to the EU market for domestic pharmaceutical companies. According to an IQVIA research report, the EU, as the world’s leading biosimilar market (accounting for approximately 40% of its value), will have no corresponding biosimilars in development for approximately 71% of original biosimilars whose patents expire between 2024 and 2030, presenting a significant market opportunity. Kexing Pharma adheres to the “innovation + internationalization” strategy and has formed full-chain innovation capabilities for its antibody technology platform, with a portfolio of more than ten new drugs in the fields of antiviral, tumor, and ...
- Source: drugdu
- 88
- September 16, 2025
Zhengda Tianqing’s new drug Qinglishu approved for marketing

　　Xinhua Finance, Nanjing, September 15 (Reporter Zhu Cheng) Recently, the official website of the National Medical Products Administration showed that the injectable degarelix acetate (trademark name: Qinglishu) independently developed by China Biopharmaceutical ‘s core enterprise, Zhengda Tianqing Pharmaceutical Group, has been approved for marketing for prostate cancer patients who need androgen deprivation therapy. 　　Zhengda Tianqing’s degarelix acetate has been approved in the EU market, becoming the world’s first generic drug, and has also received provisional approval in the US. During the domestic review process, Zhengda Tianqing also launched a patent challenge, successfully invalidating two core claims of the original drug. This product also became the first drug to receive a 12-month exclusivity period since the implementation of my country’s early resolution mechanism for pharmaceutical patent disputes. 　　The early resolution mechanism for drug patent disputes, also known as the drug patent linkage system, is a mechanism to balance the development of ...
- Source: drugdu
- 86
- September 16, 2025
Sinovac Biotech partners with Auscon Biopharmaceuticals to enter the European and American biosimilar markets

　　Shanghai Securities News China SecuritiesNews (Reporter Yang Ye, Zhao Binbin) Recently, Sinovac BiotechWe have reached a strategic cooperation with Shanghai Auscon Biopharmaceutical Co., Ltd. (hereinafter referred to as “Auscon Bio”) to jointly develop the KXBS001 biosimilar, officially entering the European and American biosimilars market. 　　The European Medicines Agency (EMA) recently released a draft plan to streamline the review process for biosimilar drug development, potentially opening a “fast track” to the EU market for domestic pharmaceutical companies. According to an IQVIA research report, the EU, as the world’s leading biosimilar market (accounting for approximately 40% of its value), will have no corresponding biosimilars in development for approximately 71% of original biosimilars whose patents expire between 2024 and 2030, presenting a significant market opportunity. 　　Sinovac Biotech adheres to the “innovation + internationalization” strategy and has formed full-chain innovation capabilities for its antibody technology platform, with a portfolio of more than ten new ...
- Source: drugdu
- 103
- September 16, 2025
Novartis and Monte Rosa Therapeutics Announce $5.7 Billion Licensing Agreement Deal for Protein Degraders

Novartis announced a licensing agreement with Monte Rosa Therapeutics valued upwards of $5.7 billion that aims at developing drugs for immune-mediated diseases. “We are pleased to expand our collaboration with Monte Rosa Therapeutics, building on the strong foundation and progress established through the VAV1 program,” said Fiona Marshall, Ph.D., president of biomedical research at Novartis. “This new agreement underscores our commitment to advancing targeted protein degradation as a promising approach to address immune-mediated diseases with high unmet need. We believe Monte Rosa’s QuEEN platform has the potential to uncover new insights in this field. We look forward to working together to translate these insights into transformative therapies for patients.”2 What are the details of the deal? Under the terms of the agreement, Novartis will pay Monte Rosa an upfront payment of $120 million (along with holding the potential to earn milestone payments and royalties), which brings the total to $5.7 ...
- Source: drugdu
- 134
- September 16, 2025
Bariatric Fusion Vitamins Pulled for Missing Child-Safe Caps

MONDAY, Sept. 15, 2025 (HealthDay News) — About 4,700 bottles of Bariatric Fusion iron-containing multivitamins have been recalled because packaging does not meet federal safety standards, according to the U.S. Consumer Product Safety Commission (CPSC). The bottles, sold online at Amazon.com, bariatricfusion.com and other sites between January and June 2025, were made without child-resistant caps. Without this protection, children could open the bottles and swallow the vitamins, which contain high levels of iron. Accidental iron poisoning in children can cause serious injury or death. The recall involves: High ADEK multivitamin capsules (90- and 270-count bottles) One Per Day bariatric multivitamin capsules (90-count bottle) All recalled bottles contain 45 mg of iron and can be identified by lot numbers 0066J4, 0065J4, 0453B5 or 0370B5, printed on the bottom. Only bottles with smooth caps (no “push down & turn” embossing) are part of the recall. So far, no injuries have been reported, ...
- Source: drugdu
- 118
- September 16, 2025
Smoking raises the risk of all subtypes of type 2 diabetes

The characteristics of type 2 diabetes vary from patient to patient and it has been proposed that the condition is made up of four subtypes. Now, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that smoking increases the risk of the condition, regardless of subtype. The researchers in Sweden, Norway and Finland also found that people with a genetic susceptibility to develop diabetes seem more vulnerable to the adverse effects of smoking. It has previously been suggested that type 2 diabetes (T2D) can be divided into the following subtypes: SIRD (severe insulin-resistant diabetes), characterised by insulin resistance (where the body’s cells don’t respond to properly to insulin and can’t easily take up glucose from the blood); SIDD (severe insulin-deficient diabetes), characterised by a lack of insulin; MOD (mild obesity-related diabetes), associated with obesity and ...
- Source: drugdu
- 131
- September 15, 2025
Types, Triggers And New Treatments

SUNDAY, Sept. 14, 2025 (HealthDay News) — Everyone gets headaches, but not all headaches are the same. For some, they’re a quick inconvenience. For others, they can be intense, long-lasting and even disabling, disrupting daily life for days or weeks. Experts say finding the right treatment depends on identifying the type of headache and understanding what triggers it. “We define chronic headache as having more than 15 headache days per month. So, more days with headache than not,” Michael Oshinsky, a pain expert at the National Institutes of Health (NIH), told its monthly newsletter News In Health. The most common kind is a tension-type headache, often linked to stress, lack of sleep, dehydration or poor posture. Pain usually feels mild to moderate and affects both sides of the head. Migraines are another frequent cause of disabling pain. Unlike tension headaches, migraines are a complex brain condition that can cause: Severe ...
- Source: drugdu
- 160
- September 15, 2025
Dobutamine Hydrochloride Injection Passes Consistency Evaluation

On September 13, Chengyi PharmaceuticalAn announcement was released regarding the company’s drug passing the generic drug consistency evaluation. The announcement revealed that the company recently received the “Notice of Approval of Supplementary Drug Application” from the National Medical Products Administration (NMPA). The company’s dobutamine hydrochloride injection has passed the generic drug quality and efficacy consistency evaluation. The drug is available in two strengths: 2ml: 20mg and 5ml: 100mg, both of which have been approved. Dobutamine hydrochloride injection is primarily used for the short-term supportive treatment of heart failure caused by organic heart disease and post-cardiac surgery low-output syndrome. The company received the Drug Registration Approval for dobutamine hydrochloride injection (2ml:20mg) from the National Medical Products Administration (NMPA) in September 2002. In July 2024, the company submitted an application for domestic production consistency evaluation of the drug to the NMPA’s Center for Drug Evaluation, also seeking an additional 5ml:100mg strength. The ...
- Source: drugdu
- 86
- September 15, 2025
“Pharma leader ” changes! Hengrui Medicine, don’t panic

Recently, Hengrui Medicine lost its position as the “No. 1 pharmaceutical company”. In the pharmaceutical industry, BeiGene’s transcendence sends a signal. For a long time in the past, Hengrui Medicine was the undisputed leader in the pharmaceutical industry. Relying on the model of “imitation + innovation”, Hengrui has been leading the entire industry, and many of its core products once occupied half of the domestic pharmaceutical market. As early as 2021, Hengrui Medicine’s stock price continued to rise after a series of sharp increases, reaching a high of 96.7 yuan per share, and its total market value reached an astonishing 616.9 billion yuan.However, the turning point also occurred in 2021. Affected by multiple factors in the industry and the outside world, Hengrui Medicine’s growth engine gradually stalled, and the “imitation + innovation” model began to fail. In terms of performance, from 2021 to 2023, Hengrui Medicine’s revenue growth rate was ...
- Source: drugdu
- 152
- September 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.